Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ
Healthcare
Biotechnology
$15.58
▲ +1.23%
Market Cap
$2.00B
Sector
Healthcare
Industry
Biotechnology
Beta
1.45
52-Wk Range
7.285-16.88
CEO
Kevin C. Tang
Country
CA
Currency
USD
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Open full interactive analysis & DCF →